INKT Stock Summary and Trading Ideas (Mink Therapeutics | NASDAQ:INKT)

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Mink Therapeutics trades on the NASDAQ stock market under the symbol INKT.

As of January 6, 2026, INKT stock price declined to $12.04 with 5,659 million shares trading.

INKT has a beta of -0.54, meaning it tends to be less sensitive to market movements. INKT has a correlation of 0.00 to the broad based SPY ETF.

INKT has a market cap of $56.52 million. This is considered a Micro Cap stock.

In the last 3 years, INKT traded as high as $76.00 and as low as $.46.

The top ETF exchange traded funds that INKT belongs to (by Net Assets): VTI, VXF.

INKT has outperformed the market in the last year with a price return of +1257.4% while the SPY ETF gained +18.1%. However, in the short term, INKT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -19.8% vs +3.7% return in SPY. But in the last 2 weeks, INKT shares have fared better than the market returning +3.3% compared to SPY +1.0%.

INKT support price is $11.38 and resistance is $12.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INKT shares will trade within this expected range on the day.